Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • phase 3 trials
FDA Approves Once-Daily Vizz (Aceclidine Ophthalmic Solution 1.44%) for Presbyopia: Clinical Implications and Evidence Review
Posted inClinical Updates Wellness & Lifestyle

FDA Approves Once-Daily Vizz (Aceclidine Ophthalmic Solution 1.44%) for Presbyopia: Clinical Implications and Evidence Review

Posted by By MedXY 08/02/2025
The FDA has approved Vizz, a once-daily aceclidine ophthalmic solution, for presbyopia in adults based on robust phase 3 data. The eye drop offers up to 10 hours of improved near vision with a favorable safety profile.
Read More
  • How Should Diabetic Patients Consume Fruits?
  • 30 Practical Tips for Effective and Healthy Weight Loss
  • Can Merely Seeing Infection Activate Real Immunity? The Neuroscience of Virtual Pathogens and Immunological Anticipation
  • One Exercise Session Can Fight Cancer! Latest Study Confirms: These Two Exercise Types Instantly Produce Anti-Cancer Substances That Significantly Inhibit Cancer Cell Growth
  • The Science of Sleep: Optimal Bedtime and Its Impact on Health
  • About us
  • Contact us
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease Antibiotics breast cancer cancer prevention cardiovascular health clinical trial clinical trials colorectal cancer Dementia diabetes diagnosis diet epidemiology exercise FDA FDA approval health healthcare HIV Hypertension immunotherapy longevity men's health mental health nutrition obesity older adults Pediatrics Pregnancy prevention probiotics public health randomized trial semaglutide sexual health sleep stroke targeted therapy treatment type 2 diabetes Vaccine weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top